Hemodynamic effects of ambrisentan-tadalafil combination therapy on progressive portopulmonary hypertension

Intravenous epoprostenol is recommended for World Health Organization functional class (WHO-FC) IV patients with pulmonary arterial hypertension (PAH) in the latest guidelines. However, in portopulmonary hypertension (PoPH) patients, advanced liver dysfunction and/or thrombocytopenia often makes the...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:World J Hepatol
Main Authors: Yamashita, Yu, Tsujino, Ichizo, Sato, Takahiro, Yamada, Asuka, Watanabe, Taku, Ohira, Hiroshi, Nishimura, Masaharu
Formato: Artigo
Idioma:Inglês
Publicado: Baishideng Publishing Group Inc 2014
Assuntos:
Case Report
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4243157/
https://ncbi.nlm.nih.gov/pubmed/25429321
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4254/wjh.v6.i11.825
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares